Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicole Cobo

Neurology with Special Qualifications in Child Neurology Long Beach, CA Medical Doctor

NPI 1497954119 CMS profile 1089036

2880 Atlantic Ave, Suite 260, Long Beach, CA 90806

Open in the dashboard

General payments

$32,501

690 records reported · program years 2019–2025

Research payments

$33,660

Paid to them · 5 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$220,079 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Nicole Cobo of Long Beach, CA is reported in the CMS Open Payments database as having received $32,501 across 690 general payments and $33,660 in research payments paid to them. Separately, studies naming them as principal investigator received $220,079 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 94th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $9,199 126
2025 Research $33,660 5
2024 General $11,625 103
2023 General $2,625 119
2022 General $3,498 74
2021 General $2,098 98
2020 General $1,758 90
2019 General $1,698 80

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicole Cobo
  • Neurology with Special Qualifications in Child Neurology median
  • Middle half of Neurology with Special Qualifications in Child Neurology
  • National median

In program year 2025, general payments to Nicole Cobo were reported at $9,199. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.

Show as a table
Year Nicole Cobo Neurology with Special Qualifications in Child Neurology median Middle half National median
2019 $1,698 $262 $68–$1,313 $163
2020 $1,758 $188 $46–$1,222 $114
2021 $2,098 $183 $45–$1,356 $132
2022 $3,498 $229 $72–$1,177 $149
2023 $2,625 $269 $93–$1,195 $160
2024 $11,625 $300 $98–$1,428 $164
2025 $9,199 $276 $87–$1,522 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $8,901 26 payments
  2. UCB, Inc. $6,305 143 payments
  3. UCB Biosciences Inc. $5,630 1 payment
  4. SK Life Science, Inc. $1,345 49 payments
  5. AbbVie, Inc. $1,300 60 payments
  6. Neurelis, Inc. $950 51 payments
  7. Corium, Inc. $602 28 payments
  8. Greenwich Biosciences, Inc. $519 17 payments
  9. Supernus Pharmaceuticals, Inc. $486 13 payments
  10. Sunovion Pharmaceuticals Inc. $430 9 payments
  11. Other $6,034 293 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $16,692 649 payments
  2. Consulting Fee $8,190 3 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $7,160 3 payments
  4. Education $459 35 payments
Products named General payments · program years 2019–2025
  1. Epidiolex $9,304 42 payments
  2. Fintepla $6,934 39 payments
  3. Briviact $3,764 84 payments
  4. VALTOCO $950 51 payments
  5. Azstarys $602 28 payments
  6. UBRELVY $557 27 payments
  7. QULIPTA $507 23 payments
  8. Hizentra $426 15 payments
  9. Qelbree $299 3 payments
  10. Nayzilam $288 10 payments
  11. Other $7,174 335 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. UCB Biosciences Inc. $33,660 5 payments

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

335

Median for Neurology: 833

Drug cost

$442,196

Median for Neurology: $202,670

Branded share of claims

50.7%

Median for Neurology: 25.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Epidiolex Cannabidiol (Cbd) Brand 17 $131,460
Xcopri Cenobamate Brand 73 $105,829
Fintepla Fenfluramine Hcl Brand 13 $105,110
Briviact Brivaracetam Brand 15 $32,849
Onfi Clobazam Brand 13 $20,401
Lamictal Lamotrigine Brand 22 $13,386
Rufinamide Generic 13 $12,633
Lacosamide Generic 20 $10,589
Clobazam Generic 20 $5,837
Oxcarbazepine Generic 13 $1,578

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,695 Part D prescribers listed as Neurology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$9,270

Medicare's payments for the services billed

Medicare patients

20

Average age 40

Services billed

71

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Atrial fibrillation 0%
Chronic kidney disease 0%
COPD 0%
Cancer 0%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Epidiolex
  • JAZZ PHARMACEUTICALS INC. $7,882
$7,882 17 —
Briviact
  • UCB, Inc. $955
$955 15 —
Fintepla
  • UCB, Inc. $403
$403 13 —
Qelbree
  • Supernus Pharmaceuticals, Inc. $299
$299 — —
VALTOCO
  • Neurelis, Inc. $286
$286 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

695 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Neurology with Special Qualifications in Child Neurology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record